Cough Relief Medications

Introduction to Cough Relief

• The combination of loratadine, ambroxol, and guaifenesin is not recommended for cough relief due to insufficient evidence supporting its effectiveness, particularly since loratadine has been found ineffective for treating acute cough associated with rhinitis, as noted by the American College of Physicians 1
• Newer generation antihistamines like loratadine are ineffective in treating acute cough associated with rhinitis, whereas first-generation antihistamines are more effective for non-histamine-mediated cough due to their anticholinergic properties 1
• First-generation antihistamines may be effective for non-allergic cough, but nonsedating antihistamines like loratadine are limited to allergic conditions, such as allergic rhinitis 1

Recommended Treatments

• First-generation antihistamines plus decongestants are recommended due to their anticholinergic effects, as suggested by the American College of Physicians 1
• Nasal corticosteroids are first-line therapy, and nonsedating antihistamines like loratadine may be effective specifically for allergic rhinitis, with a strength of evidence supporting their use 1
• For chronic bronchitis, peripheral cough suppressants like levodropropizine are recommended for short-term relief, with moderate evidence supporting their effectiveness 2
• Guaifenesin may provide modest symptomatic relief for short-term use (7-10 days) in acute upper respiratory infections with productive cough, according to the American College of Physicians and American College of Chest Physicians (ACCP) 3, 4

Medication Selection and Pitfalls

• Using second-generation antihistamines like loratadine for non-allergic cough is ineffective; first-generation antihistamines are more appropriate due to their anticholinergic properties, with high evidence supporting this recommendation 1
• Over-the-counter combination cold medications are not recommended until randomized controlled trials prove effectiveness, as stated by the CDC and American College of Physicians 2
• The American Academy of Otolaryngology-Head and Neck Surgery recommends saline nasal irrigation as a more effective alternative to guaifenesin for relieving congestion, with topical intranasal steroids also being a recommended option, and a strength of evidence supporting their use 5
• Evidence-based alternatives for chronic respiratory conditions include:

Medication Mechanism and Safety

• Guaifenesin works as an expectorant by loosening mucus in the airways, making coughs more productive, and improving mucociliary clearance, with established efficacy for acute upper respiratory tract infections with productive cough, stable chronic bronchitis with mucus hypersecretion, and possibly rhinosinusitis with mucus production, as noted by the FDA and OTC Monograph regulations 7
• Guaifenesin is generally safe when used as directed, but common side effects include gastrointestinal disturbances, dizziness, headache, and rash (rare), although rare but serious adverse events have been reported with overdose, according to the FDA and OTC Monograph regulations 4, 7
• The standard recommended dosage of Mucinex (guaifenesin) for adults is 200-400 mg every 4 hours, not to exceed 2400 mg in 24 hours for immediate-release formulations, and 600-1200 mg every 12 hours for extended-release formulations, with specific recommendations varying by age group, as stated by the FDA and OTC Monograph regulations 7
• Benzonatate acts as a peripheral anesthetic that suppresses cough by anesthetizing stretch receptors in the lungs, and is recognized by the ACCP as an effective option for opioid-resistant cough in patients with lung cancer, particularly when other agents are ineffective, with moderate evidence supporting its use 8
• Dextromethorphan is a centrally-acting cough suppressant that works on the cough center in the brain, but has serotonergic properties and should be used cautiously in patients taking other serotonergic medications, with monitoring for mental status changes, neuromuscular hyperactivity, and autonomic hyperactivity, as noted by the American College of Chest Physicians (ACCP) 9, 10

Patient Expectations and Education

• Patients should have realistic expectations about the benefits of guaifenesin, which appear to be modest at best for short-term symptomatic relief, and evidence does not support its use beyond symptomatic relief, as recommended by the American College of Chest Physicians (ACCP) and American Academy of Otolaryngology-Head and Neck Surgery, with a strength of evidence supporting this recommendation 4, 7
• Patients with chronic bronchitis or bronchiectasis should avoid using cough suppressants, as recommended by the BMJ in 2020, due to the risk of sputum retention 7